-
Recent Advances in Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer
02 Apr 2025 16:42 GMT
… institutional research funding from Genentech/Roche, Merck, … negative breast cancer: pitfalls and progress. NPJ Breast Cancer. 2022 … triple-negative breast cancer (TNBC). Clin Breast Cancer. 2024; … in triple negative breast cancer. Breast Cancer Res.;19(1): …
-
Global HER2-Negative Breast Cancer Market: Key Trends, Market Share, Growth Drivers, And Forecast For 2025-2034
26 Mar 2025 17:54 GMT
… in breast cancer cases, increased awareness about breast cancer, increased … Breast Cancer Market?
The escalating incidence of breast cancer … HER2-negative breast cancer market forward. Breast cancer, characterized by … notable example is Genentech Inc., a US …
-
Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis
02 Apr 2025 16:03 GMT
… potentially devastating diseases.
Genentech and Roche are … neuroscience today.
About Genentech Access Solutions
Access … cancers (malignancies) including breast cancer: Follow your healthcare provider … screening guidelines for breast cancer.
Inflammation of the …
-
Healthcare Resource Utilization and Cost Comparison Between Palbociclib, Abemaciclib, and Ribociclib Among Patients with HR+/HER2− Metastatic Breast Cancer
25 Mar 2025 19:05 GMT
… Role: Pfizer, MacroGenics, Genentech, Sermonix, Arvinas, Stemline, … therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5 … HER2-negative metastatic breast cancer. NPJ Breast Cancer. 2023;9( … 47;HER2- metastatic breast cancer. NPJ Breast Cancer. 2022;8(1 …
-
Breast Cancer Therapeutics Market Size to Reach US$ 63.9 Billion by 2030, Driven by Innovations and Growing Demand, Says The Insight Partners
19 Mar 2025 11:53 GMT
… Inc
Merck & Co Inc
Genentech Inc
Teva Pharmaceutical Industries Ltd … burden of breast cancer is propelling the breast cancer therapeutics market growth. Breast cancer is the …
-
Roche settles UPenn suit alleging patent infringement by Herceptin, 3 other breast cancer meds
15 Mar 2025 01:13 GMT
… four of Roche’s breast cancer meds infringed its intellectual … deliberations by March 24.
Genentech confirmed with Fierce Pharma … anti-ErbB antibodies in breast cancer: intravenous Herceptin and the … its invention.
The four breast cancer drugs at the center …
-
SERDs, PROTAC, and CERANs Offer Hope Following ET/CDK4/6 Inhibitor Resistance in Breast Cancer
10 Mar 2025 21:28 GMT
… La Roche AG/Genentech, Inc., Gilead Sciences … breast cancer. Presented at: 42nd Annual Miami Breast Cancer … breast cancer (mBC). Presented at: 2024 San Antonio Breast Cancer … metastatic breast cancer. Presented at: 2024 San Antonio Breast Cancer Symposium …
-
Inavolisib Expands the PIK3CA-Mutated Metastatic HR+ Breast Cancer Treatment Paradigm: With Virginia Kaklamani, MD, DSc
10 Mar 2025 21:26 GMT
… ’s episode, supported by Genentech, we had the pleasure … , locally advanced or metastatic breast cancer. Dr Kaklamani is a … to the HR-positive metastatic breast cancer treatment paradigm, and considerations … On Air, supported by Genentech. Check back on Mondays …
-
Subcutaneous adjuvant regimen for breast cancer reduces ‘time toxicity’ of treatment
05 Mar 2025 19:39 GMT
…
Subcutaneous administration of a breast cancer therapy significantly decreased treatment … stage I HER2-positive breast cancer spent getting treatment compared … question
Trastuzumab (Herceptin, Genentech) and pertuzumab (Perjeta, Genentech) launched as IV …
-
Advancing Care for Metastatic Breast Cancer: Oncology Pharmacists Tackle Innovation, Biomarkers, and Operational Hurdles
28 Feb 2025 20:40 GMT
… in ESR1-mutated metastatic breast cancer (MBC) management, biomarker … biomarker testing recommendations for breast cancer, but they currently … patients with advanced breast cancer with ESR1 mutations, … as capecitabine (Xeloda; Genentech, Inc), might have been …
About
© 1995-2025